Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Cancer Registry (NCR)

Definition A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives - To measure cancer incidence
- To describe cancer by time, place, persons and disease
- To provide a national database for further epidemiological research
Case definition Target cases are:
- Incident cases by year of diagnosis
- Malignant tumors confirmed by histopathology and/or hematology findings
- Cancers of all sites
Sources of data Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting).
1) The capture system: 
The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms:
- Directly from their clinic; or
- Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients
2) The recapture system: 
The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3).
The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor.
The structure is C##.# M####/##, where:
- C##.# specifies the primary site
- M#### specifies the histology
- /## specifies the behavior and the grade of the tumor
Reporting form NCR reporting form
    ...
    12
    ...
ATC Name B/G Ingredients Dosage Form Price
M01AH05 CONSORT G Etoricoxib - 120mg 120mg Tablet, film coated 309,084 L.L
M01AH05 COXIFLAM G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 2mg 2mg Tablet, film coated 2,956,454 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
J01DC02 CEFUZIME G Cefuroxime (axetil) - 500mg 500mg Tablet, film coated 490,503 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 804,962 L.L
C10AA07 CONSIVAS 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 450,187 L.L
C10AA07 CRESOTAB G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 517,379 L.L
C10AA07 CRESULIP 10 G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
N06BX03 CEBROTONIN G Piracetam - 800mg 800mg Tablet, film coated 577,852 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 804,962 L.L
C10AA07 CONSIVAS 20 G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 450,187 L.L
C10AA07 CRESOTAB G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 517,379 L.L
C10AA07 CRESULIP 20 G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 575,933 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 804,962 L.L
A11AB CYPRO-VITA B Vitamin C - 20mg, Vitamin B3 - 5mg, Vitamin B12 - 2.5mg, Vitamin B6 - 0.6mg, Vitamin B2 - 0.75mg, Vitamin B1 - 0.6mg, Vitamin D3 - 167IU, Vitamin A - 1670IU, Cyproheptadine HCl - 4mg Tablet, film coated 409,552 L.L
C09DA03 CO-DIOVAN B Valsartan - 80mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 602,041 L.L
C09DA03 CO-DIOVAN B Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 846,621 L.L
L01BC06 CAPECITABINE ACCORD G Capecitabine - 500mg 500mg Tablet, film coated 10,908,012 L.L
C09DA03 CO-ANGINET G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 544,256 L.L
L01BC06 CAPECITABINE GP PHARM G Capecitabine - 500mg 500mg Tablet, film coated 8,869,508 L.L
C09DA03 CO-TABUVAN G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 544,256 L.L
L01BC06 CAPECITABINE NEAPOLIS G Capecitabine - 500mg 500mg Tablet, film coated 11,222,829 L.L
L01BC06 CAPECITABINE SPC G Capecitabine - 500mg 500mg Tablet, film coated 12,665,771 L.L
L01BC06 CAPEDA G Capecitabine - 500mg 500mg Tablet, film coated 4,927,423 L.L
C09DA03 CO-DIOVAN B Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 901,718 L.L
L01BC06 CAPECITABINE SPC G Capecitabine - 150mg 150mg Tablet, film coated 4,094,240 L.L
C07AB07 CONCOR B Bisoprolol fumarate - 5mg 5mg Tablet, film coated 837,017 L.L
C09DA04 CO APROVEL B Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 20mg Tablet, film coated 1,251,117 L.L
    ...
    12
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025